1. Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines

3. Introduction/Overview

4. Pharmacologic Therapy for T2DM: ADA/EASD 2018 Recommendations

5. Drug-Specific Factors to Consider When Selecting T2DM Therapy: Metformin

6. Decision Cycle for Patient-Centered Glycemic Management in T2DM

7. Agent Selection Criteria for Patients With T2DM Without ASCVD or CKD

8. Meta-Analysis of GLP-1 RA and SGLT2I Trials: CVD

9. Meta-Analysis of GLP-1 RA and SGLT2I Trials: HHF

10. Meta-Analysis of GLP-1 RAs and SGLT2s: CKD (Narrow Renal Endpoints)

11. Are SGLT2I Renal Benefits eGFR Dependent?

12. CREDENCE: Study Design and Results

13. EMPA-REG Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

14. EMPA-KIDNEY

15. Obesity as a Risk Factor for a Number of Disease States and Risk Factors

16. ACCORD -- Hypoglycemia

17. Clear-Cut Clinical Roles for SGLT2Is and GLP-1 RAs

18. Summary and Conclusions

19. Abbreviations

20. Abbreviations (cont)